voriconazole

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: voriconazole
• 英文别名: VOR；(2R,3S)-2-(2,4-difluorophenyl)-3-(3-fluoropyridin-4-yl)-1-(1,2,4-triazol-1-yl)butan-2-ol
• 化学式: C₁₇H₁₅F₃N₄O
• 分子量: 348.328
• InChiKey: ODPXVNWGCWYWBD-APPDUMDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  63.8
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-氟吡啶 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 生成 voriconazole
  参考文献：
  名称：

  Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus

  摘要：

  Replacement of one triazole ring of fluconazole with 4-pyridinyl leads to an increase in activity against Aspergillus fumigatus. Introduction of an alpha-methyl group has a marked additional beneficial effect. Investigation of pyridinyl and pyrimidinyl analogues resulted in the identification of 30 (UK-109,496, voriconazole) which has excellent potency against a broad range of fungal pathogens including A. fumigatus and Candida krusei. Copyright (C) 1996 Elsevier Science Ltd.

  DOI：

  10.1016/0960-894x(96)00363-0

文献信息

• Compositions and methods for the treatment of fungal infections
  申请人：Cellix Bio Private Limited

  公开号：US11220493B2

  公开（公告）日：2022-01-11

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.

  本发明涉及这些化合物或其药用可接受的多晶型物、溶剂、对映体、立体异构体和水合物。包含有效量的式 I、式 II、式 III、式 IV、式 V、式 VI、式 VII、式 VIII、式 IX 或式 X 化合物的药物组合物以及治疗真菌感染的方法可配制成口服、口腔、直肠、局部、透皮、透粘膜、锭剂、喷雾剂、静脉注射、口服溶液、颊粘膜层片剂、肠外给药、糖浆或注射剂。此类组合物可用于治疗真菌感染。
• Triazole antifungal agents
  申请人：Pfizer Limited

  公开号：EP0440372B1

  公开（公告）日：1993-06-02
• DERIVATIVES OF MUPIROCIN
  申请人：Beecham Group p.l.c.

  公开号：EP0544705A1

  公开（公告）日：1993-06-09
• JPH04211078A
  申请人：——

  公开号：JPH04211078A

  公开（公告）日：1992-08-03
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
  申请人：Cellix Bio Private Limited

  公开号：US20210053950A1

  公开（公告）日：2021-02-25

  The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.